Sonic Healthcare (SHL) investor relations material

Executive summary

• Revenue reached $9.65 billion (A$9,645 million), up 8% year-over-year, with organic revenue growth of 5%.

• EBITDA was $1.73 billion (A$1,702 million, constant currency), up 8%, with normalized EBITDA margin expanding by 40 basis points.

• Net profit increased 7% to $514 million, and cash generated from operations rose 21%.

• EPS for the year was 106.7¢, up 6%.

• The business is well positioned for future growth, with market-leading brands and a strong balance sheet.

Financial highlights

• FY2025 revenue up 8% year-over-year; EBITDA up 8%; net profit up 7%.

• Organic revenue growth was 5%, and normalized EBITDA margin expanded by 40 basis points to 18.4%.

• Dividend for the year was $1.07 per share, up 1% year-over-year.

• Earnings per share increased 6% to 106.7 cents.

• Net interest-bearing debt rose to A$2,818 million, with a gearing ratio of 24.7%.

Outlook and guidance

• FY2026 EBITDA guidance: $1.87–1.95 billion (constant currency), or $1.94–2.02 billion at current exchange rates, up to 13% growth.

• EPS growth of up to 19% expected for FY2026 at current exchange rates.

• Interest expense expected to rise 15–20% due to acquisitions; effective tax rate around 27%.

• Guidance excludes potential PAMA fee cuts and assumes no major regulatory changes or interest rate shifts.

• Strong EPS growth expected, supported by organic growth, synergies, and acquisitions.